Home » Xolair for Young Asthmatics Rejected by Committee
Xolair for Young Asthmatics Rejected by Committee
November 20, 2009
An FDA advisory committee voted 10–4 not to recommend that the FDA expand Genentech and Novartis’ asthma drug Xolair’s indication to
treat children age 6 to 11 with moderate-to-severe persistent asthma.